
Regency Centers
REG · NASDAQ · Real Estate
Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time
- Market cap
- $14,0 bn
- Div. yield
- 4,4%
- Year to date
- +10,3%
Ratio score
based on 7 metrics as of 16.11.2026 ·
Verdict by our methodology based on current metrics. Not an investment recommendation.
Key metrics
3 ✓ · 2 — · 2 ✕ · 3 n/a · hover over a row or tap it to see the trend
All metrics
| Metric | Value | 5-year median | Industry median |
|---|---|---|---|
| P/E TTM | 26,5 | 28,5 | 32,0 |
| Forward P/E | 29,6 | — | 33,1 |
| PEG | 1,0 | — | 1,2 |
| P/S | 8,5 | 8,7 | 7,5 |
| EV/EBITDA | 19,0 | 18,8 | 19,3 |
| P/FCF | 49,3 | — | 41,0 |
| P/B | 2,0 | 1,9 | 2,7 |
Industry median — across 28 profitable companies in “Real Estate” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.
Price chart
Compare with
Choose a stock
Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.
Analysts
Ratings, 24 analysts
- Buy
- 14
- Hold
- 10
- Sell
- 0
Beat the EPS forecast in 3 of the last 4 quarters
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| Q3 2026 | 0,61 | 0,41 | Down −32,9% |
| Q2 2026 | 0,60 | 0,61 | Up +1,1% |
| Q1 2026 | 0,63 | 0,68 | Up +7,4% |
| Q4 2025 | 0,59 | 0,68 | Up +15,3% |
Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.
Financials in charts
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 412 m | 404 m | 388 m | 381 m | 381 m | 373 m | 360 m | 357 m | 364 m | 360 m | 331 m | 314 m |
| EPS | — | — | — | — | — | — | — | — | — | — | — | — |
| Margin | 32,2% | 51,5% | 29,1% | 28,4% | 29,4% | 23,8% | 28,7% | 29,4% | 31,0% | 25,6% | 27,9% | 28,1% |
| FCF | 153 m | 204 m | 219 m | 244 m | 161 m | 191 m | 228 m | 203 m | 168 m | 172 m | 213 m | 173 m |
From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.
Owners
Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.
Insider trades over 12 months
Over 12 months: no purchases, sales $39,9 m.
| Name | Amount | Shares | Price |
|---|---|---|---|
| devereaux terah l12 Jun 2026 · sale | $99 367 | 1 240 | $80,14 |
| wibbenmeyer nicholas andrew5 May 2026 · sale | $626 715 | 7 927 | $79,06 |
| stein martin e jr4 May 2026 · sale | $507 030 | 6 460 | $78,49 |
| stein martin e jr4 May 2026 · sale | $12,4 m | 157 892 | $78,39 |
| stein martin e jr4 May 2026 · sale | $8,64 m | 110 263 | $78,40 |
| stein martin e jr11 Mar 2026 · sale | $2,93 m | 38 000 | $77,21 |
| stein martin e jr10 Mar 2026 · sale | $10,1 m | 129 490 | $78,33 |
| stein martin e jr20 Feb 2026 · sale | $763 001 | 10 000 | $76,30 |
| roth alan todd10 Feb 2026 · sale | $616 400 | 8 000 | $77,05 |
| mas michael j10 Feb 2026 · sale | $1,15 m | 15 000 | $76,85 |
| palmer lisa10 Feb 2026 · sale | $2,00 m | 26 000 | $76,75 |
SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.
About the company
- Industry
- Real Estate
- Exchange
- NASDAQ
- Country
- US
- IPO date
- 29 Oct 1993
- Website
- www.regencycenters.com
Company description, revenue by segment and region, and the CEO will come later.
Earnings
- Next report
- date not announced
An AI summary of the earnings call will come later.
Peers
| Company | Price | ||||
|---|---|---|---|---|---|
DOCHealthpeak Properties | $19,84 | 56★★★★★★★★would watch | 37,4 | +9,4% | 13,7% |
MAAMid-America Apartment Communities | $117,82 | 31★★★★★★★would not consider | 35,3 | +0,8% | 17,6% |
CPTCamden Property Trust | $99,16 | 63★★★★★★★★would watch | 41,0 | +61,9% | 7 565,9% |
WYWeyerhaeuser | $20,68 | 33★★★★★★★would not consider | 32,3 | −1,1% | 6,5% |
INVHInvitation Homes | $27,10 | 75★★★★★★★★★would consider | 22,7 | +7,2% | 23,5% |
Ratio — a score by our methodology, not an investment recommendation.




